News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
Photo taken from: Debyani Chakravarty / Twitter
Jul 17, 2023, 09:59

Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty

My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.

Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).

 

Source: Debyani Chakravarty / Twitter

FDA OncoDaily Oncology zenocutuzumab
Special Coverage
Blog
Aug 1, 2025, 19:24
Oliver Bogler: What Reviewers Hate to See
Science
Aug 1, 2025, 19:18
Wolfgang Miesbach: How Far Will AI Reach? Stanford's Virtual Lab's Breakthrough
Blog
Aug 1, 2025, 19:14
The Impact Your Support Makes in the Fight Against Cancer - NFCR
Blog
Aug 1, 2025, 19:10
YARN: An Ambitious, Bold and Promising EU-Funded Initiative - Youth Cancer Europe
Science
Aug 1, 2025, 19:04
Karen Knudsen: Science in Action - Men with Advanced Prostate Cancer Benefit
Positive
Aug 1, 2025, 18:57
Two Behaviour Change Campaigns Are the Finalists at 2025 Effie Awards - Cancer Institute NSW
Career
Aug 1, 2025, 18:52
Brian A. Walker Joins Sylvester Myeloma Institute - Sylvester Comprehensive Cancer Center
Blog
Aug 1, 2025, 18:42
Identifying and Preparing Eligible Patients for Screening with Confidence - ACS NLCRT
Insight
Aug 1, 2025, 18:37
Miguel Bronchud: SEOM Has Published the 2025 Medical Oncology Research Dossier in English
Blog
Aug 1, 2025, 18:32
Sharon Kapambwe: Representing WHO in Uzbekistan
Blog
Aug 1, 2025, 18:14
Turn Knowledge Into Expertise and Refined Practical Skills - European School of Oncology
Blog
Aug 1, 2025, 18:02
"Moving Mountains With Passion": A Legacy of Purpose in European Oncology - CancerWorld